Strategies for safeguarding client confidentiality and compliance

Strategies for safeguarding client confidentiality and compliance

Everyone is aware that data breaches and cyber attacks are on the rise globally. It affects organisations across various industries and for legal firms especially it is imperative that security is a top priority. Lawyers need to ensure their documentation is secure to uphold the principles of client confidentiality and attorney-client privilege, this is fundamental to the legal profession. By securing documentation, legal professionals protect against unauthorised access, data breaches, and potential disclosure of confidential information to third parties. Compliance with legal and industry-specific regulations is crucial,and secure documentation ensures adherence to these standards, mitigating the risk of legal and ethical consequences. Additionally, securing documentation reflects the professional responsibility of legal practitioners to safeguard the interests of their clients and maintain the highest ethical standards in the practice of law.

Law firms can enhance their security measures by using cloud-based digital dictation solutions as well as implementing a combination of technical safeguards, best practices, and employee training. Here are key steps law firms can take to protect themselves when utilising cloud-based digital dictation.
Continue reading “Strategies for safeguarding client confidentiality and compliance”

Life Sciences Yearbook 2024: Sponsored foreword – Herbert Smith Freehills

Life Sciences Yearbook 2024: Sponsored foreword – Herbert Smith Freehills

‘Economic and geopolitical pressures continued throughout 2023, making the global business landscape a volatile one. It might even be asked whether disruption is simply the new business norm.’

Global themes in 2023 and outlook

The disruption felt globally at the end of 2022 continued to impact life sciences companies and investors in 2023. Continue reading “Life Sciences Yearbook 2024: Sponsored foreword – Herbert Smith Freehills”

Lead partner: The year the United Kingdom becomes a globally leading life sciences hub?

Lead partner: The year the United Kingdom becomes a globally leading life sciences hub?

As part of its ambition for the United Kingdom to become a tech and science superpower by 2030, in 2023, the government announced a range of initiatives aimed at boosting investment and innovation in the life sciences sector. Innovators will have welcomed the R&D tax relief reforms whilst the Mansion House Compact (the largest UK pension providers committing 5% of their assets to unlisted equities by 2030) announced in July has provided some hope of alternative pools of capital to unlisted UK life sciences companies.

Whilst the impact of those initiatives remains to be seen (and of course with a general election looming) the UK life sciences industry is being positioned to play an integral part in the growth of the country’s economy with many recent legal and regulatory developments also seeking to enhance the attractiveness of the UK as a leading life sciences hub. The UK’s offer to prospective investors will be centred around access to innovation, the financial firepower of the City, the introduction of progressive and pragmatic regulation and a robust advisory ecosystem, which it hopes will allow it to differentiate itself from the EU.
Continue reading “Lead partner: The year the United Kingdom becomes a globally leading life sciences hub?”

Sponsored thought leadership: China life sciences – Transaction insights and notable industry trends

Sponsored thought leadership: China life sciences – Transaction insights and notable industry trends

China’s life sciences and healthcare (LS&H) industry underwent an unprecedented transformation in 2023 consisting of numerous challenges and opportunities. Within this year, BD transactions primarily included out-licensing of ex-China rights, China commercialisation partnering, asset acquisition and regaining drug product rights, which reflected the courage of China’s LS&H market players to proactively seek changes and rebuild corporate strategies in a quickly shifting market landscape.

Fangda Partners’ life sciences team remained active in advising on LS&H corporate transactions in 2023 and recent key deal highlights included (a) Hengrui Pharma (600276.SH)’s out-licensing partnership with Aiolos Bio to exploit the innovative anti-TSLP mAb (SHR-1905) outside of Greater China; (b) Kanghua Biological (300841.SZ)’s grant of exclusive rights to HilleVax for exploitation of recombinant hexavalent VLP norovirus vaccine outside of Greater China; (c) CStone Pharma (2616.HK)’s sale of the Tibsovo® (Ivosidenib) business, asset and goodwill thereof in Greater China and Singapore to Les Laboratoires Servier; and (d) a number of commercialisation arrangements entered into by multinational pharmaceutical companies with leading CSOs. Continue reading “Sponsored thought leadership: China life sciences – Transaction insights and notable industry trends”

Sponsored Q&A: Fangda Partners

Sponsored Q&A: Fangda Partners

1. What are the current regulatory frameworks governing the life sciences industry in China, and how have they evolved in recent years?

Legislation wise, the Drug Administration Law and its implementation rules are pivotal to the pharmaceutical sector, overseeing the entire lifecycle of chemical and biological products. For medical devices (including in-vitro diagnostics), the Regulations for the Supervision and Administration of Medical Devices form a fundamental framework. Continue reading “Sponsored Q&A: Fangda Partners”

Sponsored thought leadership: Healthcare and pharmaceutical regulation in Portugal

Sponsored thought leadership: Healthcare and pharmaceutical regulation in Portugal

The health sector in Portugal, which encompasses the pharmaceutical market, is a prominent and fast-evolving sector that has undergone significant growth in recent decades.

Sérvulo & Associados law firm is proud to have a highly specialised, experienced and well-balanced team in the life sciences field. The team covers all the main legal matters of the health and pharmaceutical industry, acting and providing guidance on a broad range of issues. These include patent trademark litigation within the pharmaceutical sector, but also advice on regulatory matters, data privacy for clinical research, and patient support programmers, as well as distribution and supply agreements to the industry. Continue reading “Sponsored thought leadership: Healthcare and pharmaceutical regulation in Portugal”

How do you know when you have a brand advantage?

How do you know when you have a brand advantage?

By Sholto Lindsay-Smith, founding partner and director of brand strategy at Industry, an international brand and business consultancy.

As the management mantra goes, ‘you can’t manage what you can’t measure’. Law firms often undertake evaluation of their brand in pockets throughout the organisation by teams in HR, customer experience, internal and external communications. What is often missing is a 360-view which can summarise the brand strategy, identify brand-blockers and determine where to invest efforts in building brand advantage. This article considers the importance in assimilating this information to build a lasting brand advantage. Continue reading “How do you know when you have a brand advantage?”

Sponsored briefing: The lateral partner hiring landscape for 2024

Sponsored briefing: The lateral partner hiring landscape for 2024

I have been working with law firms advising on strategic lateral partner hires for more than 20 years, and trying to predict what the market is going to do is not only challenging but futile, as the market often does exactly the opposite of what everyone thinks it is going to do.

Law firm growth and profitability is directly linked to hiring and developing the right people, be that as trainees, or as lateral partner hires. Even firms that have historically grown organically, such as the Magic Circle or single-office big hitters like Macfarlanes and Travers Smith, are increasingly making forays into the lateral recruitment market. This desire/need/pressure to grow and to get ahead of the curve has exploded in recent years and resulted in record numbers of partner and team moves, not to mention some eye-catching mergers.
Continue reading “Sponsored briefing: The lateral partner hiring landscape for 2024”

Sponsored Q&A: PwC

Sponsored Q&A: PwC

1. What are the key regulatory bodies overseeing the banking and finance sector in Poland, and what is their role in ensuring compliance with financial laws and regulations?

The main supervisory body in Poland is the Polish Financial Supervisory Authority (‘Komisja Nadzoru Finansowego’ or ‘KNF’). KNF supervises the banking, capital, insurance and pension sectors, payment institutions and payment service offices, electronic money institutions and credit unions. Continue reading “Sponsored Q&A: PwC”

Sponsored briefing: Mitigating the risks of the current economic climate

Sponsored briefing: Mitigating the risks of the current economic climate

Oktay Şener, managing partner of Aksan Law Firm, examines how his team has reacted to the changing Turkish legal market

How are the recent economic problems, including the currency crash and inflation, affecting your firm?

Experiencing difficulties is quite normal in the current economic climate and unfortunately, we also witness the reflections of this issue among our clients. However, our country’s economic history and past have accustomed us to such ups and downs. At Aksan, in line with the precautions we have taken after Covid, we have been discussing, contemplating and implementing measures related to this situation for a while now.
Continue reading “Sponsored briefing: Mitigating the risks of the current economic climate”